Chongqing Guanzan is a medical distributor with distribution channels covering over 4,000 pharmacies, over 4,000 clinics, 50 hospitals and 130 pharmaceutical companies nationwide
Image: BOQI International Medical acquires Chongqing Guanzan Technology. (Credit: FreeDigitalPhotos.net/adamr.)
BOQI International Medical has completed the acquisition of Chongqing Guanzan Technology Co.
Chongqing Guanzan is a medical distributor with distribution channels covering over 4,000 pharmacies, over 4,000 clinics, 50 hospitals and 130 pharmaceutical companies nationwide. Chongqing Guanzan also has about ten world-leading medical device suppliers such as Stryker, GE, Siemens, Philips and Olympus. Recent important business updates of Chongqing Guanzan related to COVID-19 treatment include:
On March 2, 2020, Chongqing Guanzan was authorized as the distributor of Jilin Morestep Medical’s disposable protective coverall in Chongqing.
On February 1, 2020, Chongqing Guanzan was authorized as the distributor of Nanjing Chenwei’s medical ventilator and anesthesia machine in Chongqing.
On January 1, 2020, Chongqing Guanzan was authorized as the distributor of Shenzhen Lanmage’s digital radiography in Chongqing.
As previously disclosed, on February 1, 2020, the Company entered into a stock purchase agreement (the “Agreement”) with BEIJING XIN RONG XIN INDUSTRIAL DEVELOPMENT CO., LTD., a company organized under the laws of the People’s Republic of China (the “PRC”) (“Buyer”), Chongqing Guanzan, a company organized under the laws of the PRC and Zhou Li, an individual residing in the PRC (“Seller”). Pursuant to the Agreement, Buyer, a wholly-owned subsidiary of the Company, will purchase all the issued and outstanding shares (the “Guanzan Shares”) of Chongqing Guanzan from Seller. The aggregate purchase price for the Guanzan Shares is RMB 100,000,000 (estimated at $14,285,714), to be paid in 950,000 shares of common stock of the Company (the “Stock Consideration”) and RMB 80,000,000 in cash (the “Cash Consideration”). The Stock Consideration was scheduled to be paid at closing and the Cash Consideration, which is subject to post-closing adjustments based on the performance of Chongqing Guanzan in 2020 and 2021, respectively, will be paid pursuant to a post-closing payment schedule.
The transaction was closed on March 18, 2020 (“Closing”). Upon Closing, the Guanzan Shares were transferred to and recorded under the name of Buyer and the Stock Consideration was paid to Seller through the issuance of 950,000 shares of the Company’s common stock in accordance with the Agreement.
“We have recently received several medical device orders from home and abroad,” said Mr. Xiaoping Wang, Chief Executive Officer of Chongqing Guanzan and Chief Operation Officer of BOQI International Medical Inc. “Our most urgent mission is to provide our domestic and international clients, including hospitals, clinics and other medical institutions, with the necessary supplies and equipment for COVID-19 treatment. This partnership allows us to continue to provide quality products to our customers with the more efficient logistic process and integrated supply chain of a premier public company.”
“The acquisition is aimed at a more accessible and affordable health care experience for consumers. This is particularly critical in times of a pandemic, ” said Mr. Tiewei Song, Chief Executive Officer and President of BOQI International Medical Inc. “As long as COVID-19 continues to be a threat, we’ll maintain a relentless focus on how best to serve our customers. We will leverage all the recourses, develop telehealth tools and engage more healthcare partners to make it easier for customers to access the information, supplies and services they need to achieve their best health.”
Source: Company Press Release